Marksans Pharma Shares Extended Gains For Second Straight Day

On November 26, 2024, Marksans Pharma’s stock saw a notable surge, climbing over 7% in morning trading. This increase led the stock to reach a new 52-week and all-time high of ₹344 on the NSE. The company outperformed the sector by 5.2% during today’s trading session, marking its second consecutive day of gains. Over the past two days, Marksans Pharma shares have increased by over 8%.

Strong Performance Over Recent Months

Marksans Pharma’s strong momentum extends beyond just the current trading day. Over the past six months, the company’s shares have delivered an impressive return of 100.86%. Looking at a one-year period, the stock has risen by 134.86%, reflecting its consistent growth and investor confidence. As of November 25, 2024, the Nifty Healthcare Index also saw a positive movement, rising by 0.76% to reach 14,102.15. In comparison, Marksans Pharma’s performance has surpassed sector growth by 5.2%, underscoring its outperformance relative to its peers.

USFDA Approval for Loratadine Tablets

In a significant development, Marksans Pharma recently announced receiving final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg. This product, a generic version of Bayer Healthcare’s Clartin tablet, is used to treat allergic rhinitis and upper respiratory tract allergies. Loratadine is an antihistamine that alleviates common allergy symptoms, including runny nose, itchy eyes, and sneezing.

Marksans Financial Performance: Q2 FY25 Results

Marksans Pharma reported strong financial results for Q2 FY25. The company posted operating revenue of Rs. 641.9 crore, reflecting a 20.8% year-on-year increase, driven by robust performances in key markets, particularly the US and Australia/New Zealand (ANZ). Gross profit stood at Rs. 383.5 crore, marking a 37.7% YoY growth, with a notable expansion in gross margin by 732 basis points, reaching 59.7%. This growth is attributed to the softening of raw material prices and an improved product mix.

About Marksans Pharma Ltd

Marksans Pharma is a prominent player in the pharmaceutical industry, specializing in the formulation of pharmaceutical products. The company focuses on both over-the-counter (OTC) and prescription drugs, which cover a wide range of therapeutic areas, including Oncology, Gastroenterology, Antidiabetics, Antibiotics, Cardiovascular health, Pain Management, and Gynaecology.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.